BRPI0622074A8 - Anticorpos de pdgfralfa - Google Patents

Anticorpos de pdgfralfa

Info

Publication number
BRPI0622074A8
BRPI0622074A8 BRPI0622074A BRPI0622074A BRPI0622074A8 BR PI0622074 A8 BRPI0622074 A8 BR PI0622074A8 BR PI0622074 A BRPI0622074 A BR PI0622074A BR PI0622074 A BRPI0622074 A BR PI0622074A BR PI0622074 A8 BRPI0622074 A8 BR PI0622074A8
Authority
BR
Brazil
Prior art keywords
pdgfra
antibodies
medicaments
manufacture
pdgfralfa
Prior art date
Application number
BRPI0622074A
Other languages
English (en)
Inventor
R Plymate Stephen
Loizos Nick
Huber Jim
Fatatis Alessandro
L Ludwig Dale
Original Assignee
Philadelphia Health & Education D/B/A Drexel Univ College Of Medicine
Imclone Systems Incorporated
Imclone Llc
Univ Washington
Univ Drexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health & Education D/B/A Drexel Univ College Of Medicine, Imclone Systems Incorporated, Imclone Llc, Univ Washington, Univ Drexel filed Critical Philadelphia Health & Education D/B/A Drexel Univ College Of Medicine
Publication of BRPI0622074A2 publication Critical patent/BRPI0622074A2/pt
Publication of BRPI0622074A8 publication Critical patent/BRPI0622074A8/pt
Publication of BRPI0622074B1 publication Critical patent/BRPI0622074B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS DE PDGFRa. A invenção fornece usos de um antagonista IGF-IRa e/ou PDGFRa na fabricação de medicamentos para tratar câncer ósseo, em particular o câncer ósseo metastático. A invenção fornece também anticorpos que se ligam aos PDGFRa humanos e neutralizam a ativação dos receptores. A invenção ainda fornece um método para neutralizar a ativação de PDGFRa, e um uso do anticorpo isoladamente ou em combinação com outros agentes na fabricação de medicamentos para tratar uma doença neoplásica.
BRPI0622074-6A 2005-06-17 2006-06-19 Anticorpo ou fragmento de anticorpo humano isolado específico para pdgfr-alfa, polinucleotídeo e vetor de expressão BRPI0622074B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69192005P 2005-06-17 2005-06-17
US60/691.920 2005-06-17
PCT/US2006/023856 WO2006138729A2 (en) 2005-06-17 2006-06-19 Receptor antagonists for treatment of metastatic bone cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611984-0A Division BRPI0611984A2 (pt) 2005-06-17 2006-06-19 uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo

Publications (3)

Publication Number Publication Date
BRPI0622074A2 BRPI0622074A2 (pt) 2011-07-19
BRPI0622074A8 true BRPI0622074A8 (pt) 2017-10-10
BRPI0622074B1 BRPI0622074B1 (pt) 2023-08-22

Family

ID=

Also Published As

Publication number Publication date
JP2009106306A (ja) 2009-05-21
EP2100614A3 (en) 2010-02-17
WO2006138729A3 (en) 2009-02-12
KR101246504B1 (ko) 2013-03-26
CA2680945A1 (en) 2006-12-28
CY1114603T1 (el) 2016-10-05
BE2017C007I2 (pt) 2026-02-02
EP1909819A2 (en) 2008-04-16
ES2435727T3 (es) 2013-12-23
EP2100618B1 (en) 2014-02-12
BRPI0622074A2 (pt) 2011-07-19
BRPI0622073A2 (pt) 2011-07-19
IL198869A0 (en) 2010-02-17
EP1909819A4 (en) 2010-02-17
EP2505205A1 (en) 2012-10-03
NL300869I2 (nl) 2017-05-24
IL198869A (en) 2011-09-27
ES2452115T3 (es) 2014-03-31
RU2455026C3 (ru) 2020-04-08
EP2100614A2 (en) 2009-09-16
EP2100618A2 (en) 2009-09-16
CA2612449A1 (en) 2006-12-28
LUC00012I1 (pt) 2017-04-06
US8574578B2 (en) 2013-11-05
JP2009102444A (ja) 2009-05-14
RU2455026C2 (ru) 2012-07-10
HUS1700015I1 (hu) 2017-07-28
CN101613409A (zh) 2009-12-30
IL198870A (en) 2013-03-24
CA2678008C (en) 2013-07-30
RU2008101772A (ru) 2009-07-27
EP2100618A3 (en) 2010-06-09
LTC2100614I2 (lt) 2018-03-26
BRPI0611984A2 (pt) 2009-07-07
RU2009115363A (ru) 2010-10-27
CA2680945C (en) 2014-03-18
CY2017013I2 (el) 2017-07-12
JP2009501141A (ja) 2009-01-15
CN101612399A (zh) 2009-12-30
BRPI0622073A8 (pt) 2017-10-03
CN101500597A (zh) 2009-08-05
PT2100618E (pt) 2014-04-07
US20090110678A1 (en) 2009-04-30
EP2100614B1 (en) 2013-10-09
US20120027767A1 (en) 2012-02-02
KR20080047529A (ko) 2008-05-29
CY2017013I1 (el) 2017-07-12
KR101246428B1 (ko) 2013-03-21
CN101613409B (zh) 2014-06-04
PT2100614E (pt) 2013-12-16
CA2678008A1 (en) 2006-12-28
CN101612399B (zh) 2013-11-27
LTPA2017011I1 (lt) 2017-05-10
KR20090027774A (ko) 2009-03-17
EP2100614B8 (en) 2013-11-20
KR20090027773A (ko) 2009-03-17
RU2009115364A (ru) 2010-10-27
DK2100614T3 (da) 2013-10-28
US20120034244A1 (en) 2012-02-09
RU2502523C2 (ru) 2013-12-27
IL198870A0 (en) 2010-02-17
CY1115076T1 (el) 2016-12-14
HK1135917A1 (en) 2010-06-18
JP5436883B2 (ja) 2014-03-05
US8128929B2 (en) 2012-03-06
US8425911B2 (en) 2013-04-23
JP2012179060A (ja) 2012-09-20
IL188151A0 (en) 2008-03-20
PL2100618T3 (pl) 2014-07-31
SI2100614T1 (sl) 2014-03-31
JP5154470B2 (ja) 2013-02-27
LUC00012I2 (pt) 2017-06-19
PL2100614T3 (pl) 2014-02-28
DK2100618T3 (en) 2014-03-03
SI2100618T1 (sl) 2014-03-31
WO2006138729A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
HRP20060033B1 (hr) Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute
UA94899C2 (ru) Фиксированное дозирование антител к her
BRPI0819916A2 (pt) Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
PA8804901A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
BRPI0818437A8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
BRPI0612624A2 (pt) métodos para tratar doença vascular em um humano, e para prevenção e/ou tratamento de uma doença induzida por trombose ou uma doença induzida por tromboembolismo em um humano, e, uso de um composto
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSITY OF WASHINGTON (US) , DREXEL UNIVERSITY

B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF WASHINGTON (US) , DREXEL UNIVERSITY

B25A Requested transfer of rights approved

Owner name: IMCLONE LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.